Skip to main content
Search
Newsletters
Watchlist
Home
Watchlist
For You
Canada
World
Business
Investing
Personal Finance
Opinion
Politics
Sports
Life
Arts
Drive
Real Estate
Latest in
TSX Today:
ENB-T
-0.04%
MFC-T
+1.06%
GWO-T
+0.35%
SU-T
+0.76%
CVE-T
+1.14%
FTS-T
-0.13%
TD-T
+0.62%
Search stocks, ETFs and Commodities
Instrument Name
Lyell Immunopharma Inc
Instrument Symbol
(LYEL-Q)
Instrument Exchange
NASDAQ
Add to Watchlist
Create Alerts
USD
Today's Change
Real-Time
Last Update
Last Sale
Cboe BZX Real-Time
USD
After Hours
Change
After Hours
Last Update
After Hours
Price
Volume
Summary
Charts
Profile
Financials
Statistics
Dividends
Price History
Analyst Estimates
Insiders
Lyell Immunopharma Inc
201 HASKINS WAY
SOUTH SAN FRANCISCO CA 94080 USA
P:
650-695-0677
http://www.lyell.com
Sectors & Indices
Sector
Industry
Employees
SIC-2834 Pharmaceutical Preparations
Medical - Drugs
Indices Nasdaq Composite
Indices Russell 2000
Indices Russell 3000
Profile
Lyell Immunopharma Inc. is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Lyell Immunopharma Inc. is based in SOUTH SAN FRANCISCO, Calif.
Key Executives
Name
Title
Lynn Seely
CEO/Director/President
Matthew Lang
Other Executive Officer
Charles Newton
CFO/Chief Accounting Officer
Stephen Hill
COO
Gary Lee
Chief Scientific Officer
More from The Globe
Dividend investing has lost its mojo. Here’s why – and how to adapt
Ian McGugan
Yesterday
The Globe Investing Club 2024: Let the competition begin!
Yesterday
opinion
Here’s the real reason your Canadian stocks can’t keep up
Tim Shufelt
Yesterday
Dow ends above 40,000 milestone, TSX also at fresh record high
Yesterday
number cruncher
U.S technology stocks with earnings and price momentum
May 16, 2024
Lightspeed Commerce stock soars on better-than-expected profit forecast
May 16, 2024
GameStop, AMC dive further as meme stocks rally tapers off
May 16, 2024
The close: Dow briefly hits 40,000 milestone, TSX rises on upbeat earnings
May 16, 2024